BEAM-302
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alpha 1-Antitrypsin Deficiency
Conditions
Alpha 1-Antitrypsin Deficiency
Trial Timeline
Jun 19, 2024 → May 1, 2030
NCT ID
NCT06389877About BEAM-302
BEAM-302 is a phase 1/2 stage product being developed by Beam Therapeutics for Alpha 1-Antitrypsin Deficiency. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06389877. Target conditions include Alpha 1-Antitrypsin Deficiency.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06389877 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Alpha 1-Antitrypsin Deficiency